ArticleWorld journal of microbiology & biotechnology2025
Escherichia coli O157:H7 prevalence in Upper Egypt: impacts on food safety and human Health, with a protection trial using natural antibacterial Piper cubeba.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cryptosporidiosis at the human-ruminant interface in Aswan, Egypt: a one health epidemiological study using microscopy, immunofluorescence, and PCR.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli O157:H7 has been linked to intestinal infections in humans and is thought to be a major cause of foodborne illnesses. The research is providing an update on the prevalence and toxin profile of multidrug-resistant E. coli O157:H7 in Upper Egypt, from November 2023 to February 2024. A total of 410 samples were obtained from food products, animals, water, and human stool for isolation, identification, and serotyping of multidrug-resistant E. coli O157:H7 by using traditional and molecular techniques. Furthermore, the antibacterial effect of Piper cubeba Linn. (PcL) extract against E. coli O157:H7 was studied in vitro. E. coli and E. coli O157:H7 were found to have a prevalence of 28% and 8%, respectively, with the highest occurrence in human stool. Depending on serology, 12 different E. coli serotypes were identified in the overall samples. The PCR showed that the most virulence genes found were Stx1 (42.4%), followed by uidA (39.4%), eaeA (36.4%), hlyA (30.3%), and Stx2 (15.2%). Furthermore, blaTEM (42.4%), tetA (36.4%), and Aada1 (27.3%) are the most common resistance genes. Most strains were resistant to ampicillin, penicillin G, and tetracycline (100% each), while florfenicol and ciprofloxacin were entirely sensitive. Furthermore, all concentrations of PcL extract (0.5%, 1%, 3%, and 5%) confirmed significant inhibitory activities against E. coli O157:H7 with MIC values of 0.43 mg/mL to 0.74 mg/mL and MBC values of 0.86 mg/mL to 1.76 mg/mL. These results could assist in preserving human health by increasing awareness of the dangers posed by this bacterium and lowering the prevalence of illnesses linked to E. coli O157:H7. This study proposes that PcL extract could be employed as a natural antimicrobial additive in food products, which creates new opportunities for its advancement and application in functional foods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.